Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPodiatryAetna Metatarsal Phalangeal Joint Coverage Update …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0708

    Metatarsal Phalangeal Joint Replacement

    Customize your policy alerts

    Sign up for Aetna Policy 0708 alerts

    Get alerted when Policy 0708 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing coverage and medical necessity for metatarsal phalangeal (first MTP) joint replacement procedures and related implants for Aetna members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyMetatarsal Phalangeal Joint Replacement
    Policy CodePolicy 0708
    Change TypeNo material change
    Effective DateOct 28, 2005
    Last ReviewOct 3, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain and document failed nonoperative management and baseline pain/function measures to support prior authorization and medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2procedures medically necessary
    7+implants experimental/investigational (examples)
    28291example covered CPT code
    68-92%implant survival (select series)
    24%reported revision rate (ToeFit-Plus)

    Coverage Criteria — First Metatarsophalangeal (MTP) Joint Replacement

    Medically necessary procedures

    Aetna considers the following procedures medically necessary for persons with disabling arthritis of the first metatarsophalangeal (first MTP) joint (hallux rigidus):

    Medically necessary procedures: Procedures considered medically necessary for disabling first MTP arthritis

    1) Hemiarthroplasty; 2) Total prosthetic replacement arthroplasty with silastic implants (e.g., the In2Bones Reference Toe System (RTS) Implant).

    Experimental and investigational

    Aetna considers the following devices and procedures experimental and investigational for metatarsal phalangeal joint replacement because effectiveness and durability have not been established:

    Experimental/Investigational implants: Specific named implants and technologies

    Includes: Accu-Joint Hemi Implant; bioabsorbable RegJoint; ceramic prostheses (e.g., Moje); interpositional arthroplasty with biologic spacers; total metallic implants for hallux rigidus; modular implants (Arthrex, Cartiva, METIS, OsteoMed ReFlexion, ToeFit-Plus); Roto-Glide; and replacement for indications not listed in medically necessary section.

    Comparative effectiveness and evidence summary

    Evidence-based stance summary

    Evidence summary: Randomized and comparative studies generally show arthrodesis provides superior pain relief, higher satisfaction, fewer revisions, and more predictable outcomes than MTP joint arthroplasty; implant-specific series report variable survival and notable rates of loosening, subsidence, and revisions.

    See device-specific outcomes for metallic implants, modular systems, and synthetic cartilage implants in the Background.

    Coverage considerations and comparative evidence

    Evidence-based considerations when choosing a surgical option for hallux rigidus:

    Evidence summary: Arthrodesis generally demonstrates superior pooled improvement in AOFAS-HMI score and greater pain reduction compared with total joint replacement; pooled analyses report fewer revisions with arthrodesis.

    Systematic reviews and pooled studies support arthrodesis superiority for outcome and lower revision rates.

    Implant-specific outcomes to consider: Implant performance varies: some modular and metallic implants report early improvements but higher mid- to long-term revision/failure rates; synthetic cartilage (Cartiva) demonstrated equivalent short-term pain and function to arthrodesis with low rates of fragmentation/wear but with up to ~9% conversion to fusion by 2 years and additional revisions over mid-term follow-up.

    See individual study outcomes (ToeFit-Plus, Cartiva, modular systems).

    Patient selection: Consider motion-sparing options for patients who prioritize preserved first MTP motion and accept higher revision risk; prefer arthrodesis when durable pain relief and lower revision risk are primary goals.

    Based on randomized trials and systematic reviews.

    Evidence-based outcome criteria (trial definitions)

    Clinical trial-derived outcome criteria and common clinical endpoints reported in the literature:

    Cartiva RCT composite success (per-study): (1) >=30% reduction in VAS pain from baseline at 12 months; (2) maintenance of function on FAAM Sports sub-score at 12 months; (3) absence of major safety events at 2 yearsas stated

    Primary composite endpoint used in Baumhauer et al. randomized non-inferiority study.

    Clinical indications and selection considerations

    Clinical indications and selection considerations discussed in the literature:

    Indications discussed: Advanced-stage hallux rigidus (grades 2–4 in trial populations) and symptomatic end-stage 1st MTP arthritis failing nonoperative therapyclinical judgment

    Multiple studies evaluated these populations for hemiarthroplasty, synthetic cartilage implants, or arthrodesis.

    Selection considerations: Assess etiology and prior surgery (e.g., prior distal metatarsal osteotomy increasing risk of AVN), attempt conservative and joint-sparing procedures when appropriate, and counsel patients that implant procedures may later require conversion to arthrodesis.n/a

    Concerns about enrolling patients without end-stage disease and about prior-surgery effects are noted in literature critiques.

    Clinical coverage considerations (informational)

    Clinical considerations and inferred coverage-relevant conclusions from cited studies (informational):

    Implant outcomes and informed consent: When implant arthroplasty is considered, document baseline joint range of motion and counsel patients that postoperative ROM improvement may be limited, footwear restrictions may persist, and implant failure requiring conversion to fusion is possible.

    Supported by trial reports and letters noting lack of pre-operative ROM measures and postoperative footwear limitations.

    AVN management: For avascular necrosis (AVN) of the first metatarsal head, nonoperative management is appropriate for many cases; when surgery is required, fusion is the preferred and robust surgical option.

    Edwards (2005) recommends fusion as preferred surgical treatment for symptomatic AVN.

    Comparative outcomes for Roto-Glide (RG) vs arthrodesis: In a retrospective cohort (Richter et al. 2023), RG total joint replacement showed marginally higher PROMs, greater joint motion, and slightly lower revision counts compared with arthrodesis over mid-term follow-up, but longer follow-up is needed to define deficits.

    Level III evidence; groups: 70 RG vs 72 A; modest differences in PROMs and revisions reported.

    The policy lists specific implants and implant systems that are identified as not covered for the indications described in this bulletin. Examples explicitly named include Cartiva Synthetic Cartilage Implant, OsteoMed ReFlexion 1st MTP Implant System, METIS® prosthesis, ToeFit-Plus™ prosthesis, Accu-Joint hemi implant, and the Roto-Glide implant. The CPB also notes that HCPCS codes L8641 and L8642 are not covered for the METIS and ToeFit-Plus prostheses and that the listed devices are not covered for the indications set out in this policy.

    Use of metatarsophalangeal (MTP) joint implants for toe joints other than the first MTP, or for the tarsal-metatarsal (TMT) joint, is identified as having insufficient evidence. The CPB indicates that evidence regarding safety and effectiveness for these non–first-MTP indications is lacking and therefore does not support routine coverage.

    The document highlights implant designs with consistently poor mid- and long-term outcomes and indicates these may be unacceptable choices. For example, the ToeFit-Plus is reported in multiple series with high revision or failure rates (mid-term revision rate reported as 24% in one series and long-term implant removal/failure reported near 21–37% in other reports), and investigators in several studies have discontinued use because of these results. The CPB advises documenting implant choice and counseling patients about these adverse outcome data.

    The CPB emphasizes selecting patients appropriately: individuals whose disease is amenable to less invasive, joint‑preserving procedures (for example, cheilectomy or decompression osteotomy) may be poor candidates for immediate joint‑destructive implant arthroplasty. Critics of some trials note enrollment of patients without end‑stage disease who might have favorable outcomes with joint‑sparing interventions, underscoring the need to attempt and document conservative or joint‑preserving options before implant arthroplasty.

    In the provided excerpts there are no additional explicit exclusions beyond the named devices and indication restrictions already listed; the text does not identify other standalone exclusions in these sections.

    The policy designates several implants and certain indications as experimental or investigational / not covered. Devices named as experimental/investigational or not covered for the listed indications include Cartiva, OsteoMed ReFlexion, METIS, ToeFit-Plus, Accu-Joint, the bioabsorbable RegJoint inter-positional implant, and the Roto-Glide system. The CPB also notes insufficient evidence to support use of MTP implants for non–first-MTP joints.

    Based on systematic reviews and comparative studies, the CPB states that total prosthetic replacement arthroplasty with metallic implants for hallux rigidus cannot be recommended at this time. Reviews cited concerns about conflicting and poor‑quality evidence, implant loosening and metallic breakdown, and silicone‑related synovitis, supporting a stance against routine use of metallic total prosthetic replacements for this indication.

    The CPB draws attention to implants with reported high revision or failure rates and indicates these outcomes may render such implants not medically necessary choices when safer, better‑supported alternatives exist. For example, the ToeFit‑Plus series report revision and implant‑removal rates that led authors to stop using the device; where revision risks are unacceptably high, arthrodesis or better‑performing implants may be preferred.

    While these excerpts do not present explicit, numbered 'not medically necessary' statements, the text raises concerns about enrolling patients without end‑stage disease into implant studies and emphasizes that patients should typically have had an adequate trial of conservative or joint‑sparing therapy prior to consideration of joint‑destructive implants. Such concerns may inform payer review of medical necessity on a case‑by‑case basis.

    In the provided sections there are no additional explicit 'not medically necessary' conditions stated. The document reiterates caution regarding patient selection and incomplete preoperative assessment in some trials but does not list further categorical exclusions in these excerpts.

    Coding — CPT, HCPCS, and Diagnosis Codes

    Covered CPT Codes (if selection criteria met)CPTCovered
    28291Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; with implant.
    Other related CPT codesCPT
    26535Arthroplasty, interphalangeal joint; each joint.
    26536Arthroplasty, interphalangeal joint; with prosthetic implant, each joint.
    HCPCS codesHCPCSCovered
    L8641Metatarsal joint implant [not covered for the METIS® prosthesis and the ToeFit-Plus™ prosthesis].
    L8642Hallux implant [not covered for the METIS® prosthesis and the ToeFit-Plus™ prosthesis].
    L8658Interphalangeal joint spacer, silicone or equal, each.
    HCPCS codes / implants not covered for indications listedHCPCSNot Covered
    Cartiva (no specific code)Cartiva Synthetic Cartilage Implant or OsteoMed ReFlexion 1st MTP Implant System listed as not covered for indications in the CPB.
    Roto-Glide (no specific code)Roto-Glide implant listed as not covered for indications in the CPB.
    Accu-Joint (no specific code)Accu-Joint hemi Implant listed as not covered for indications in the CPB.
    Arthrex metatarsal phalangeal joint implant (no specific code)Arthrex metatarsal phalangeal joint implant listed as not covered for indications in the CPB.
    Bioabsorbable RegJoint (no specific code)Bioabsorbable poly-L-D-lactic acid RegJoint inter-positional implant listed as not covered for indications in the CPB.
    OsteoMed ReFlexion (no specific code)OsteoMed ReFlexion 1st MTP Implant System listed as not covered for indications in the CPB.
    Covered ICD-10 Codes (if selection criteria met)ICD-10Covered
    M20.20Hallux rigidus.
    M20.21Hallux rigidus, right foot.
    M20.22Hallux rigidus, left foot.
    ICD-10 codes not covered for indications listedICD-10Not Covered
    M20.10 - M20.12Hallux valgus (listed as not covered for indications in the CPB).
    M87.071 - M87.079Idiopathic aseptic necrosis of ankle, foot and toes (listed as not covered for indications in the CPB).
    Codes not specified in this document segmentmixed
    No codes listed

    Provider Actions — Authorization, Documentation, and Clinical Steps

    Prior Authorization

    Prior authorization and required documentation

    Prior authorization is recommended for covered CPT/HCPCS codes when selection criteria are met. Provider documentation should include standardized outcome measures (e.g., AOFAS, VAS, FAAM), baseline and pre-authorization imaging, and the specific implant type, indication, and planned procedure. Include details on prior conservative therapy and rationale for selecting arthroplasty over joint-sparing options.

    • Document implant model and components (metatarsal and phalangeal components, bearing type).
    • Include objective baseline measures: ROM (dorsiflexion/plantarflexion), pain VAS, AOFAS or FAAM scores, and weight-bearing radiographs or CT.
    Documentation Required

    Consideration of arthrodesis and less invasive options

    Arthrodesis is commonly considered the gold standard for first MTP disease and should be discussed with the patient. Given higher failure and revision rates reported for some total joint replacements, providers should document that arthrodesis was considered and explain why arthroplasty is preferred in this case.

    Background — Disease and Device Context

    Background: Disease of the first metatarsophalangeal (first MTP or hallux) joint most commonly arises from osteoarthritis (hallux rigidus) but may also follow rheumatoid arthritis, sesamoid disease, or post‑traumatic degeneration. Hallux rigidus is characterized by pain and reduced range of motion, particularly dorsiflexion, and is often managed initially with conservative measures. When surgery is needed, arthrodesis (fusion) is considered the gold standard for durable pain relief and low revision rates, while arthroplasty and interpositional procedures aim to preserve motion but have variable durability and complication profiles that depend on implant design and patient selection.

    Definitions and Device Descriptions

    Hallux rigidus — definition
    DefinitionHallux rigidus: pain and reduction in range of motion, especially dorsiflexion, at the first metatarsophalangeal (first MPJ) joint.
    Clinical featuresStiffness of the great toe that can affect shoe wear, ambulation, and activities of daily living.
    Common causesOsteoarthritis, rheumatoid arthritis, disease of the hallucal sesamoids, or post-traumatic degeneration.
    Conservative managementExercise, physiotherapy, supportive shoes/orthoses, NSAIDs, and steroid injections are emphasized prior to surgery.
    Arthrodesis — definition
    DefinitionArthrodesis: surgical fusion of the first metatarsophalangeal (first MPJ) joint.
    Policy Summary
    PayerAetna
    PolicyMetatarsal Phalangeal Joint Replacement
    Policy CodePolicy 0708
    Change TypeNo material change
    Effective DateOct 28, 2005
    Last ReviewOct 3, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain and document failed nonoperative management and baseline pain/function measures to support prior authorization and medical necessity.
    SourceLink
    On This Page
    Coverage Criteria — First Metatarsophalangeal (MTP) Joint ReplacementCoding — CPT, HCPCS, and Diagnosis CodesProvider Actions — Authorization, Documentation, and Clinical StepsBackground — Disease and Device ContextDefinitions and Device Descriptions
    • Discussed arthrodesis as alternative and documented patient preference or contraindication to fusion.
    • Documented reasoning when choosing arthroplasty in younger patients or those with non–end-stage disease.
    Denial Risk

    High revision and implant failure risk — provider alert

    High revision and failure rates have been reported for some implants (for example, ToeFit-Plus and certain modular systems). These higher revision rates may prompt denials or be a factor in determining investigational status for specific implants. Providers must include long-term outcome expectations and discuss revision risk in informed consent.

    • Report known device-specific outcomes and revision rates in the record when using implants with documented higher failure.
    • Be aware that devices with unacceptably high long-term failure (e.g., ToeFit-Plus in several series) may be deemed not standard of care.
    Documentation Required

    Provider documentation: implant-specific details required

    Some modular implants and certain named devices have limited long-term data or higher re-operation rates; when using such implants, include implant type, fixation method, and indication in the operative and pre-authorization documentation. Failure to provide device-specific details may result in claim review or denial.

    • Specify implant system, fixation (press-fit, cemented, screw), and whether the device is FDA-cleared for the indication.
    • If using implants considered experimental/investigational per policy, note that coverage may be denied.
    Note

    Legal and disclaimer statements

    This Clinical Policy Bulletin is provided to assist in benefits administration and is neither a contract nor medical advice. It may be updated and does not replace clinical judgment. Participating providers are independent contractors; treating providers remain responsible for medical advice and treatment. Coverage determinations are subject to plan terms.

    • CPB content does not guarantee coverage — verify member benefits and prior authorization requirements.
    • Policy is subject to change; always confirm current requirements before scheduling procedures.
    Step Therapy

    Conservative therapy and step therapy

    No step therapy requirements or explicit step-duration thresholds are specified in this policy. Conservative therapies (exercise, physio, orthoses, NSAIDs, steroid injections) are emphasized and should be attempted and documented prior to consideration of joint-destructive procedures when clinically appropriate.

    • Document trials of conservative management and response (dates, modalities, duration).
    • If joint-sparing options (e.g., cheilectomy, osteotomy) are reasonable for the patient, document why these were not suitable before arthroplasty.
    Role in treatmentConsidered the 'gold standard' for end-stage hallux rigidus with predictable pain relief and low revision rates.
    When indicatedPreferred for severe disease or when durable pain relief is the priority over motion preservation.
    Hemiarthroplasty / Total joint arthroplasty — definition
    DefinitionHemiarthroplasty / Total joint arthroplasty: surgical replacement of part (hemi) or all (total) of the first MPJ using implanted prosthetic components intended to preserve joint motion.
    Implant typesIncludes metallic, ceramic, modular, silastic and other prostheses; outcomes vary by design.
    Outcome concernsEvidence shows variable durability with higher rates of loosening, subsidence, and revisions compared with arthrodesis in multiple studies.
    Interpositional arthroplasty — definition
    DefinitionInterpositional arthroplasty: resection arthroplasty combined with insertion of a biologic spacer (e.g., tendon or capsular tissue) into the joint to maintain motion and stability.
    RationaleAims to avoid some difficulties of simple resection by better maintaining joint length, stability, and motion.
    EvidenceAvailable studies are primarily level IV; systematic reviews conclude insufficient high-quality evidence to recommend broadly.
    ToeFit-Plus — device description
    Device descriptionToeFit-Plus: a modular implant system for hemi-arthroplasty or total replacement of the first MPJ; non-cemented and fixed by a self-tapping threaded taper.
    Design featuresModular titanium/polyethylene components designed for fixation in host bone without cement.
    Reported outcomesEarly series report significant improvements in AOFAS scores but radiolucencies and longer-term durability require further follow-up.
    Cartiva — device description
    Device descriptionCartiva: a polyvinyl alcohol hydrogel (PVA-H) synthetic cartilage implant (small 8–10 mm device) used as an alternative to arthrodesis to preserve first MTP motion.
    Trial evidenceA multicenter randomized non-inferiority trial compared Cartiva to first MTP arthrodesis with primary composite outcome including pain, function, and safety (12–24 month follow-up).
    Reported outcomesStudy reported equivalent pain relief and function at 12–24 months with maintenance of ~6.2° active dorsiflexion improvement and implant-to-arthrodesis conversions ≤10% at 2 years.
    Composite primary endpoint (Cartiva RCT) — definition
    DefinitionComposite primary endpoint (Cartiva RCT): clinical success required meeting all three criteria — (1) ≥30% reduction in VAS pain at 12 months; (2) maintenance of FAAM sports sub-score at 12 months; and (3) absence of major safety events at 2 years.
    Use in trialDefined as the study's individual-subject primary outcome for non-inferiority comparison versus arthrodesis.
    Statistical thresholdNon-inferiority declared if the one-sided 95% lower confidence limit exceeded the pre-specified equivalence margin (less than 15%).
    RTS Flexible 1st MPJ Implant — definition
    Device descriptionRTS Flexible 1st MPJ Implant: a flexible silicone great-toe implant (NuSil Med 4755) with optional titanium grommets for the first metatarsal when desired by the surgeon.
    Manufacturer/systemIn2Bones Reference Toe System (RTS) — flexible silicone elastomer implant used to treat MTP joint arthritis.
    AVN of 1st metatarsal head — definition
    DefinitionAVN of 1st metatarsal head: avascular necrosis affecting the first metatarsal head, an uncommon condition most often observed after distal metatarsal osteotomy for hallux valgus.
    Clinical courseMany cases are subclinical; symptomatic cases can cause failure of bunion surgery and may require fusion when intervention is needed.
    Management optionsNonoperative management is appropriate for most cases; surgical options include debridement/synovectomy, Keller procedure, or fusion (preferred when intervention is necessary).
    Roto-Glide (RG) implant — definition
    Device descriptionRoto-Glide (RG) implant: a specific total joint replacement device used for first MTP joint total joint replacement and studied in comparative cohorts versus arthrodesis (Richter et al. 2023).
    Comparative findingsRetrospective cohort (70 RG vs 72 arthrodesis) reported marginally higher PROMs (VASFA, EFAS), greater joint motion, more physiologic pedographic force distribution, and slightly lower revision rates for RG over mid-term follow-up.
    Evidence levelReported evidence is Level III; authors note need for longer follow-up and broader reporting to define potential deficits.